{"disease":{"id":"prophylaxis-for-hae","name":"prophylaxis for hae"},"drugs":{"marketed":[{"drug_id":"garadacimab-gxii","indication_name":"Prophylaxis for HAE","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ANDEMBRY","generic_name":"GARADACIMAB-GXII","company_name":"CSL BEHRING LLC","drug_phase":"marketed","molecular_target":"activated Factor XII (FXIIa and βFXIIa)","drug_class":"","quality_score":41,"revenue":null,"mechanism":"Garadacimab-gxii inhibits activated FXII, reducing the activation of prekallikrein and bradykinin generation, thereby decreasing inflammation and swelling in HAE attacks."},{"drug_id":"donidalorsen","indication_name":"Prophylaxis for HAE attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dawnzera","generic_name":"DONIDALORSEN","company_name":"Ionis Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Dawnzera works by binding to a specific messenger RNA molecule to prevent the production of a faulty protein that causes hereditary angioedema."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}